Compare Danaher Corporation (DHR) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Vanguard Ultra Short Bond ETF — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Vanguard Ultra Short Bond ETF trades at $49.49 (market cap $10.20B). The key difference: Danaher Corporation is far larger — about 15× Vanguard Ultra Short Bond ETF's market cap, and Danaher Corporation pays a 0.74% dividend while Vanguard Ultra Short Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Vanguard Ultra Short Bond ETF for 62 Days on average.
| DHR | VUSB | |
|---|---|---|
Market Cap | $152.87B | $10.20B |
Volume | 5,228,698 | 2,664,667 |
Sector | Health | Leveraged / Inverse |
52-Week High | $242.05 | $50.03 |
52-Week Low | $161.91 | $49.41 |
Typical Hold Time | 69 Days | 62 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
VUSB trades at $49.49, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend, while recent news highlights short-term bond ETF appeal amid potential Fed rate hikes. The company has announced upcoming dividends, with three distributions scheduled for H2-2026.
The outlook remains cautious due to bearish technicals and interest rate sensitivity. Opportunities include dividend income, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term stability against macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
